Get started
Celldex Therapeutics, Inc.Celldex Therapeutics, Inc.Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsForecastSeasonalsETFs

TCE2 chart


Full chart

TCE2 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.45 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.555 EUR
Net income (FY)
‪−152.49 M‬ EUR
Revenue (FY)
‪6.78 M‬ EUR
Shares float
‪64.52 M‬
Beta (1Y)
1.56

Employees


Employees (FY)
186
Change (1Y)
+26 +16.25%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Celldex Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Anthony S. Marucci
Website
celldex.com
Headquarters
Hampton
Founded
1983
ISIN
US15117B2025
FIGI
BBG000D8VKX2
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Check out other big names from the same industry as TCE2.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TCE2 news



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Celldex Therapeutics, Inc. stocks are traded under the ticker TCE2.
We've gathered analysts' opinions on Celldex Therapeutics, Inc. future price: according to them, TCE2 price has a max estimate of 76.83 EUR and a min estimate of 25.61 EUR. Watch TCE2 chart and read a more detailed Celldex Therapeutics, Inc. stock forecast: see what analysts think of Celldex Therapeutics, Inc. and suggest that you do with its stocks.
TCE2 reached its all-time high on Oct 1, 2021 with the price of 49.960 EUR, and its all-time low was 1.390 EUR and was reached on Mar 19, 2020. View more price dynamics on TCE2 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Celldex Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Celldex Therapeutics, Inc. is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
TCE2 earnings for the last quarter are −0.72 EUR per share, whereas the estimation was −0.73 EUR resulting in a 0.68% surprise. The estimated earnings for the next quarter are −0.77 EUR per share. See more details about Celldex Therapeutics, Inc. earnings.
Celldex Therapeutics, Inc. revenue for the last quarter amounts to ‪619.70 K‬ EUR, despite the estimated figure of ‪873.89 K‬ EUR. In the next quarter, revenue is expected to reach ‪864.84 K‬ EUR.
TCE2 net income for the last quarter is ‪−48.05 M‬ EUR, while the quarter before that showed ‪−49.73 M‬ EUR of net income which accounts for 3.37% change. Track more Celldex Therapeutics, Inc. financial stats to get the full picture.
No, TCE2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 26, 2025, the company has 186 employees. See our rating of the largest employees — is Celldex Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Celldex Therapeutics, Inc. EBITDA is ‪−196.44 M‬ EUR, and current EBITDA margin is ‪−2.73 K‬%. See more stats in Celldex Therapeutics, Inc. financial statements.
Like other stocks, TCE2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Celldex Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.